Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833064 | 0.83 | KDM4E (0.64) | MLYCDMEN1KMT2AKDM4EPLAU | |
| SCHEMBL1515914 | 0.83 | CES2 (0.53) | MLYCDMEN1KMT2ATDP1KDM4E | |
| SCHEMBL1421627 | 0.83 | MEN1 (0.56) | LMNAMLYCDMEN1KMT2ATDP1 | |
| SCHEMBL13694024 | 0.81 | MLYCD (0.48) | MLYCDKDM4EPLAUCLK1DYRK1A | |
| SCHEMBL13694026 | 0.81 | MLYCD (0.44) | MLYCDMEN1KMT2AKDM4EPLAU | |
| SCHEMBL935497 | 0.80 | PARP1 (0.50) | LMNAL3MBTL1MLYCDMEN1KMT2A | |
| SCHEMBL7600387 | 0.80 | HPGDS (0.46) | NCEH1MEN1KMT2ATDP1 | |
| SCHEMBL15447357 | 0.80 | ALDH1A1 (0.41) | NCEH1MLYCDMEN1KMT2ATDP1 | |
| SCHEMBL13566 | 0.80 | MALT1 (0.43) | NCEH1LMNAL3MBTL1MLYCDMEN1 | |
| SCHEMBL11057263 | 0.79 | NCEH1 (0.46) | NCEH1LMNAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9433609-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-06 | — | — | US | disclosed |
| US-9433609-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-06 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | NCEH1 1411/4885LMNA 3064/4885L3MBTL1 1834/4885 |
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | NCEH1 236/4885LMNA 3258/4885L3MBTL1 1638/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | NCEH1 1483/4885LMNA 2786/4885L3MBTL1 1563/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | NCEH1 236/4885LMNA 3258/4885L3MBTL1 1638/4885 |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | HAVCR2, CBR3, ZC3HAV1 | NCEH1 3364/4885LMNA 4586/4885L3MBTL1 2477/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | NCEH1 1483/4885LMNA 2786/4885L3MBTL1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.